Article info
PDFOriginal articles
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review
- Correspondence to:
Dr A Clegg Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, University of Southampton, Southampton SO16 7PX, UK;
a.clegg{at}soton.ac.uk
Citation
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review
Publication history
- Accepted August 16, 2001
- Revised August 8, 2001
- First published January 1, 2002.
Online issue publication
September 01, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2002 Thorax